American College of Medical Toxicology

GENERAL INFORMATION

• Course Brochure




• Daily Agenda

HOTEL INFORMATION 

Catamaran Resort Hotel & Spa
San Diego, CA  

With its tropical design and beachfront setting, the Catamaran has so much to offer! Enjoy the Catamaran’s engaging San Diego activities that capture the beach style of this great city.

FEATURED SPEAKERS

Sidney M. Wolfe, MD
Director, Health Research Group, Public Citizen, Inc., Washington, DC

Presidential Keynote Address
Research-Based Drug Safety Advocacy 
March 16, 2012

Prior to co-founding the Health Research Group with Ralph Nader in 1971, Sidney M. Wolfe, M.D. began working at the National Institutes of Health in 1966, where he did research on aspects of blood-clotting and on alcoholism. Dr. Wolfe met Ralph Nader in Washington, D.C. at a meeting of the American Patients Association, began advising Mr. Nader on health problems in America and helped in the recruitment of medical student volunteers who worked for Mr. Nader.

Dr. Wolfe has been the Director of the Health Research Group since its creation in 1971.

Since 1995 he has been an Adjunct Professor of Internal Medicine at the Case Western Reserve University School of Medicine. His medical degree is from Case Western University in Cleveland, Ohio and his internship and residency were in internal medicine. He is currently a member of the Society for General Internal Medicine.

His awards include receiving the MacArthur Foundation Fellowship in 1990.

Peter F. Fedullo, MD
Director, Medical Intensive Care Unit - Hillcrest
UC San Diego School of Medicine, La Jolla, CA

Sepsis Update: Emergency Department Physicians on the Frontline
March 16, 2012

Dr. Peter Fedullo is a Professor of Medicine in the Division of Pulmonary/Critical Care Medicine at the University of California, San Diego and currently serves as Director of the Medical Intensive Care Unit as well as a member of the Pulmonary Vascular Group at that institution.

Dr. Fedullo completed his Pulmonary/Critical Care fellowship in 1984 at the University of California, San Diego under the direction of Dr. Kenneth Moser.  Along with Dr. Moser he was involved in the evaluation and care of some of the earliest patients to successfully undergo pulmonary thromboendarterectomy.  He has been involved in the care of patients with chronic thromboembolic disease over the past 27 years and has accrued significant experience in the surgical and medical management of these patients as well as those with other variants of pulmonary hypertensive disorders.

Dr. Fedullo has served as Director of the Medical Intensive Care unit at the UCSD Hillcrest facility since 1998 and is currently heading the hospital’s initiative to improve sepsis outcomes through improved compliance with the sepsis bundle.

William Fenical, PhD 
Director, Center for Biotechnology and Biomedicince Scripps Institution of Oceanography,
UC San Diego, La Jolla, CA

Turning Marine Toxins Into Drugs
March 16, 2012

Dr. William Fenical is one of the founders of the marine natural products field. He is currently the director of the Center for Marine Biotechnology and Biomedicine (CMBB), based at the Scripps Institution of Oceanography in La Jolla, California. Scripps is part of the University of California, San Diego, and several other departments at the university are also part of the CMBB. The CMBB focuses on the discovery of new medicines from marine sources and on developing the ocean as a frontier for the future by training young people to explore and become excited about what the ocean can bring to the field of human health. Fenical is also a member of the UCSD Cancer Center, as much of his work involves collaborating with cancer physicians. Fenical's research focuses on the discovery and development of marine natural products as potential treatments mainly for cancer and infectious diseases. His work in the field, which began in the 1960s, has covered a wide range of organisms including algae, corals and sponges, but his current focus is on marine microorganisms. He studies not only their medical potential, but also basic questions about their biology such as where they grow and the roles they play in the ocean.

Phillip I. Tarr, MD
Director, Division of Pediatric Gastroenterology & Nutrition 

Escherichia coli O157:H7: The Toxin, the Target, and the Timing
March 16, 2012

Dr. Phillip I. Tarr is currently the Melvin E. Carnahan Professor of Pediatrics, and Director of the Division of Pediatric Gastroenterology and Nutrition at Washington University School of Medicine and co-directs the Pediatrics Pathobiology Research Unit, and is a Professor of Molecular Microbiology. He obtained his MD degree from Yale University School of Medicine in 1980, and completed clinical training in pediatrics, pediatric gastroenterology and pediatric infectious diseases at the University of Washington/Seattle Children’s Hospital, where he remained on the faculty until 2003 when he assumed his present position.

Dr. Tarr has had an abiding interest in many different aspects of enteric infections, with a focus on pediatrics. His chief contributions have been in the field of diarrheagenic Escherichia coli, especially E. coli O157:H7. His work has helped delineate the epidemiology, pathophysiology, and medical management of illnesses caused by this pathogen. He has long advocated the role of accurate and thorough enteric diagnostics as a mainstay of clinical care.

CONTINUING EDUCATION

The University of Alabama School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Alabama School of Medicine designates this educational activity for a maximum of 14 AMA PRA Category 1 credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The University of Alabama School of Medicine is an equal opportunity/affirmative action institution.